ID   ASM_HUMAN               Reviewed;         629 AA.
AC   P17405; A8K8M3; E9PKS3; P17406; Q13811; Q16837; Q16841;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   03-MAR-2009, sequence version 4.
DT   10-MAY-2017, entry version 192.
DE   RecName: Full=Sphingomyelin phosphodiesterase;
DE            EC=3.1.4.12 {ECO:0000269|PubMed:15877209, ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044, ECO:0000269|PubMed:8702487};
DE   AltName: Full=Acid sphingomyelinase {ECO:0000303|PubMed:27349982};
DE            Short=aSMase;
DE   Flags: Precursor;
GN   Name=SMPD1; Synonyms=ASM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, ALTERNATIVE
RP   SPLICING, AND VARIANTS ILE-322 AND ARG-506.
RX   PubMed=1840600;
RA   Schuchman E.H., Suchi M., Takahashi T., Sandhoff K., Desnick R.J.;
RT   "Human acid sphingomyelinase. Isolation, nucleotide sequence and
RT   expression of the full-length and alternatively spliced cDNAs.";
RL   J. Biol. Chem. 266:8531-8539(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-506.
RX   PubMed=1292508;
RA   Newrzella D., Stoffel W.;
RT   "Molecular cloning of the acid sphingomyelinase of the mouse and the
RT   organization and complete nucleotide sequence of the gene.";
RL   Biol. Chem. Hoppe-Seyler 373:1233-1238(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-36.
RX   PubMed=1740330; DOI=10.1016/0888-7543(92)90366-Z;
RA   Schuchman E.H., Levran O., Pereira L.V., Desnick R.J.;
RT   "Structural organization and complete nucleotide sequence of the gene
RT   encoding human acid sphingomyelinase (SMPD1).";
RL   Genomics 12:197-205(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-157.
RX   PubMed=8407868; DOI=10.1093/oxfordjournals.jbchem.a124131;
RA   Ida H., Rennert O.M., Eto Y., Chan W.Y.;
RT   "Cloning of a human acid sphingomyelinase cDNA with a new mutation
RT   that renders the enzyme inactive.";
RL   J. Biochem. 114:15-20(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND VARIANT
RP   ARG-506.
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 128-629, PARTIAL PROTEIN
RP   SEQUENCE, ALTERNATIVE SPLICING, AND VARIANTS ILE-322 AND ARG-506.
RC   TISSUE=Fibroblast;
RX   PubMed=2555181;
RA   Quintern L.E., Schuchman E.H., Levran O., Suchi M., Ferlinz K.,
RA   Reinke H., Sandhoff K., Desnick R.J.;
RT   "Isolation of cDNA clones encoding human acid sphingomyelinase:
RT   occurrence of alternatively processed transcripts.";
RL   EMBO J. 8:2469-2473(1989).
RN   [8]
RP   CATALYTIC ACTIVITY, COFACTOR, AND SUBCELLULAR LOCATION.
RX   PubMed=8702487; DOI=10.1074/jbc.271.31.18431;
RA   Schissel S.L., Schuchman E.H., Williams K.J., Tabas I.;
RT   "Zn2+-stimulated sphingomyelinase is secreted by many cell types and
RT   is a product of the acid sphingomyelinase gene.";
RL   J. Biol. Chem. 271:18431-18436(1996).
RN   [9]
RP   GLYCOSYLATION AT ASN-86; ASN-175; ASN-335; ASN-395 AND ASN-520.
RX   PubMed=9030779; DOI=10.1111/j.1432-1033.1997.511_1a.x;
RA   Ferlinz K., Hurwitz R., Moczall H., Lansmann S., Schuchman E.H.,
RA   Sandhoff K.;
RT   "Functional characterization of the N-glycosylation sites of human
RT   acid sphingomyelinase by site-directed mutagenesis.";
RL   Eur. J. Biochem. 243:511-517(1997).
RN   [10]
RP   DISULFIDE BONDS, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12631268; DOI=10.1046/j.1432-1033.2003.03435.x;
RA   Lansmann S., Schuette C.G., Bartelsen O., Hoernschemeyer J., Linke T.,
RA   Weisgerber J., Sandhoff K.;
RT   "Human acid sphingomyelinase.";
RL   Eur. J. Biochem. 270:1076-1088(2003).
RN   [11]
RP   POLYMORPHISM.
RX   PubMed=18088425; DOI=10.1186/1471-2350-8-79;
RA   Dastani Z., Ruel I.L., Engert J.C., Genest J. Jr., Marcil M.;
RT   "Sphingomyelin phosphodiesterase-1 (SMPD1) coding variants do not
RT   contribute to low levels of high-density lipoprotein cholesterol.";
RL   BMC Med. Genet. 8:79-79(2007).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANT NPDB
RP   ASP-357.
RX   PubMed=27659707; DOI=10.1016/j.bbrc.2016.09.096;
RA   Acuna M., Castro-Fernandez V., Latorre M., Castro J., Schuchman E.H.,
RA   Guixe V., Gonzalez M., Zanlungo S.;
RT   "Structural and functional analysis of the ASM p.Ala359Asp mutant that
RT   causes acid sphingomyelinase deficiency.";
RL   Biochem. Biophys. Res. Commun. 479:496-501(2016).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, VARIANT NPDB ASP-357, AND
RP   CHARACTERIZATION OF VARIANT NPDB ASP-357.
RX   PubMed=25920558; DOI=10.1038/ejhg.2015.89;
RA   Acuna M., Martinez P., Moraga C., He X., Moraga M., Hunter B.,
RA   Nuernberg P., Gutierrez R.A., Gonzalez M., Schuchman E.H.,
RA   Santos J.L., Miquel J.F., Mabe P., Zanlungo S.;
RT   "Epidemiological, clinical and biochemical characterization of the
RT   p.(Ala359Asp) SMPD1 variant causing Niemann-Pick disease type B.";
RL   Eur. J. Hum. Genet. 24:208-213(2016).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 47-629 OF MUTANT SER-629 IN
RP   COMPLEX WITH ZINC, CATALYTIC ACTIVITY, GLYCOSYLATION AT ASN-86;
RP   ASN-175; ASN-335; ASN-395; ASN-503 AND ASN-520, DISULFIDE BONDS, AND
RP   SUBUNIT.
RX   PubMed=27349982; DOI=10.1016/j.jmb.2016.06.012;
RA   Xiong Z.J., Huang J., Poda G., Pomes R., Prive G.G.;
RT   "Structure of human acid sphingomyelinase reveals the role of the
RT   saposin domain in activating substrate hydrolysis.";
RL   J. Mol. Biol. 428:3026-3042(2016).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 47-629 OF APOENZYME AND IN
RP   COMPLEX WITH PHOSPHOCHOLINE AND ZINC, COFACTOR, AND GLYCOSYLATION AT
RP   ASN-86; ASN-175; ASN-335; ASN-395; ASN-503 AND ASN-520.
RX   PubMed=27725636; DOI=10.1038/ncomms13082;
RA   Zhou Y.F., Metcalf M.C., Garman S.C., Edmunds T., Qiu H., Wei R.R.;
RT   "Human acid sphingomyelinase structures provide insight to molecular
RT   basis of Niemann-Pick disease.";
RL   Nat. Commun. 7:13082-13082(2016).
RN   [16]
RP   VARIANT NPDA SER-577, CHARACTERIZATION OF VARIANT NPDA SER-577, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=1718266; DOI=10.1016/0006-291X(91)91697-B;
RA   Ferlinz K., Hurwitz R., Sandhoff K.;
RT   "Molecular basis of acid sphingomyelinase deficiency in a patient with
RT   Niemann-Pick disease type A.";
RL   Biochem. Biophys. Res. Commun. 179:1187-1191(1991).
RN   [17]
RP   VARIANT NPDA LEU-496.
RX   PubMed=2023926; DOI=10.1073/pnas.88.9.3748;
RA   Levran O., Desnick R.J., Schuchman E.H.;
RT   "Niemann-Pick disease: a frequent missense mutation in the acid
RT   sphingomyelinase gene of Ashkenazi Jewish type A and B patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:3748-3752(1991).
RN   [18]
RP   VARIANT NPDB ARG-608 DEL.
RX   PubMed=1885770; DOI=10.1172/JCI115380;
RA   Levran O., Desnick R.J., Schuchman E.H.;
RT   "Niemann-Pick type B disease. Identification of a single codon
RT   deletion in the acid sphingomyelinase gene and genotype/phenotype
RT   correlations in type A and B patients.";
RL   J. Clin. Invest. 88:806-810(1991).
RN   [19]
RP   VARIANT NPDA PRO-302.
RX   PubMed=1391960;
RA   Levran O., Desnick R.J., Schuchman E.H.;
RT   "Identification and expression of a common missense mutation (L302P)
RT   in the acid sphingomyelinase gene of Ashkenazi Jewish type A Niemann-
RT   Pick disease patients.";
RL   Blood 80:2081-2087(1992).
RN   [20]
RP   VARIANT NPDB ARG-436.
RX   PubMed=1301192; DOI=10.1002/humu.1380010111;
RA   Takahashi T., Desnick R.J., Takada G., Schuchman E.H.;
RT   "Identification of a missense mutation (S436R) in the acid
RT   sphingomyelinase gene from a Japanese patient with type B Niemann-Pick
RT   disease.";
RL   Hum. Mutat. 1:70-71(1992).
RN   [21]
RP   VARIANT NPDA ILE-382, AND VARIANTS NPDB ARG-242 AND SER-383.
RX   PubMed=1618760;
RA   Takahashi T., Suchi M., Desnick R.J., Takada G., Schuchman E.H.;
RT   "Identification and expression of five mutations in the human acid
RT   sphingomyelinase gene causing types A and B Niemann-Pick disease.
RT   Molecular evidence for genetic heterogeneity in the neuronopathic and
RT   non-neuronopathic forms.";
RL   J. Biol. Chem. 267:12552-12558(1992).
RN   [22]
RP   VARIANT NPDB GLY-391.
RX   PubMed=8051942; DOI=10.1007/BF00735404;
RA   Sperl W., Bart G., Vanier M.T., Christomanou H., Baldissera I.,
RA   Steichensdorf E., Paschke E.;
RT   "A family with visceral course of Niemann-Pick disease, macular halo
RT   syndrome and low sphingomyelin degradation rate.";
RL   J. Inherit. Metab. Dis. 17:93-103(1994).
RN   [23]
RP   VARIANT NPDA THR-389.
RX   PubMed=8680412; DOI=10.1002/humu.1380060412;
RA   Schuchman E.H.;
RT   "Two new mutations in the acid sphingomyelinase gene causing type A
RT   Niemann-pick disease: N389T and R441X.";
RL   Hum. Mutat. 6:352-354(1995).
RN   [24]
RP   VARIANT NPDA CYS-446.
RX   PubMed=8693491; DOI=10.1620/tjem.177.117;
RA   Takahashi T., Suchi M., Sato W., Ten S.B., Sakuragawa N.,
RA   Desnick R.J., Schuchman E.H., Takada G.;
RT   "Identification and expression of a missense mutation (Y446C) in the
RT   acid sphingomyelinase gene from a Japanese patient with type A
RT   Niemann-Pick disease.";
RL   Tohoku J. Exp. Med. 177:117-123(1995).
RN   [25]
RP   VARIANT NPDB GLN-246.
RX   PubMed=8664904;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:1<65::AID-HUMU10>3.3.CO;2-8;
RA   Ida H., Rennert O.M., Maekawa K., Eto Y.;
RT   "Identification of three novel mutations in the acid sphingomyelinase
RT   gene of Japanese patients with Niemann-Pick disease type A and B.";
RL   Hum. Mutat. 7:65-67(1996).
RN   [26]
RP   VARIANTS NPDA LYS-292 AND PRO-341.
RX   PubMed=9266408; DOI=10.1023/A:1005387932546;
RA   Pavluu H., Elleder M.;
RT   "Two novel mutations in patients with atypical phenotypes of acid
RT   sphingomyelinase deficiency.";
RL   J. Inherit. Metab. Dis. 20:615-616(1997).
RN   [27]
RP   VARIANTS NPDB VAL-49; TRP-92; PRO-137; ARG-157; PRO-196; CYS-200;
RP   MET-225; CYS-228; ASP-232; SER-245; ARG-248; HIS-289; ALA-323;
RP   ARG-330; ASP-357; HIS-376; LEU-376; PRO-379; VAL-413; TYR-421;
RP   ARG-431; PRO-432; CYS-435; VAL-452; ASP-456; TRP-474; LEU-475;
RP   LEU-480; ASN-488; SER-494; CYS-496; GLN-514; VAL-515; ARG-533;
RP   PRO-549; ASN-576; HIS-600 AND PRO-600, AND VARIANT VAL-485.
RX   PubMed=12369017; DOI=10.1086/345074;
RA   Simonaro C.M., Desnick R.J., McGovern M.M., Wasserstein M.P.,
RA   Schuchman E.H.;
RT   "The demographics and distribution of type B Niemann-Pick disease:
RT   novel mutations lead to new genotype/phenotype correlations.";
RL   Am. J. Hum. Genet. 71:1413-1419(2002).
RN   [28]
RP   VARIANTS NPDA ARG-248; TYR-319; SER-463; LEU-475 AND HIS-537, AND
RP   VARIANTS NPDB SER-371 AND ARG-608 DEL.
RX   PubMed=12556236; DOI=10.1046/j.1469-1809.2003.00009.x;
RA   Sikora J., Pavluu-Pereira H., Elleder M., Roelofs H., Wevers R.A.;
RT   "Seven novel Acid sphingomyelinase gene mutations in Niemann-Pick type
RT   A and B patients.";
RL   Ann. Hum. Genet. 67:63-70(2003).
RN   [29]
RP   VARIANTS NPDA PRO-103; SER-245; LYS-246; HIS-313; PRO-450; LEU-475;
RP   LEU-496; HIS-496 AND CYS-517, AND VARIANT GLN-294.
RX   PubMed=15221801; DOI=10.1002/humu.9258;
RA   Ricci V., Stroppiano M., Corsolini F., Di Rocco M., Parenti G.,
RA   Regis S., Grossi S., Biancheri R., Mazzotti R., Filocamo M.;
RT   "Screening of 25 Italian patients with Niemann-Pick A reveals fourteen
RT   new mutations, one common and thirteen private, in SMPD1.";
RL   Hum. Mutat. 24:105-105(2004).
RN   [30]
RP   VARIANTS NPDB PRO-103; PRO-225; CYS-244; THR-281; LYS-292 AND ILE-382.
RX   PubMed=15241805; DOI=10.1002/humu.9263;
RA   Pittis M.G., Ricci V., Guerci V.I., Marcais C., Ciana G., Dardis A.,
RA   Gerin F., Stroppiano M., Vanier M.T., Filocamo M., Bembi B.;
RT   "Acid sphingomyelinase: identification of nine novel mutations among
RT   Italian Niemann Pick type B patients and characterization of in vivo
RT   functional in-frame start codon.";
RL   Hum. Mutat. 24:186-187(2004).
RN   [31]
RP   VARIANTS NPDB ALA-130 AND TYR-563, AND CHARACTERIZATION OF VARIANTS
RP   NPDB PRO-103; ALA-130; PRO-225; CYS-244; THR-281; TYR-563; HIS-600 AND
RP   PRO-600.
RX   PubMed=16010684; DOI=10.1002/humu.9353;
RA   Dardis A., Zampieri S., Filocamo M., Burlina A., Bembi B.,
RA   Pittis M.G.;
RT   "Functional in vitro characterization of 14 SMPD1 mutations identified
RT   in Italian patients affected by Niemann Pick type B disease.";
RL   Hum. Mutat. 26:164-164(2005).
RN   [32]
RP   VARIANTS NPDA ARG-166; LEU-184; HIS-228; VAL-241; ARG-248; GLU-251;
RP   ALA-278; HIS-289; LYS-292; PRO-341; HIS-376; TRP-474; ARG-533 AND
RP   SER-577, VARIANT ARG-506, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF
RP   VARIANTS NPDA LEU-184; GLU-251; ALA-278; LYS-292; PRO-341 AND HIS-376.
RX   PubMed=15877209; DOI=10.1007/s10545-005-5671-5;
RA   Pavluu-Pereira H., Asfaw B., Poupctova H., Ledvinova J., Sikora J.,
RA   Vanier M.T., Sandhoff K., Zeman J., Novotna Z., Chudoba D.,
RA   Elleder M.;
RT   "Acid sphingomyelinase deficiency. Phenotype variability with
RT   prevalence of intermediate phenotype in a series of twenty-five Czech
RT   and Slovak patients. A multi-approach study.";
RL   J. Inherit. Metab. Dis. 28:203-227(2005).
RN   [33]
RP   VARIANTS NPDB ARG-166 AND ASN-176, AND VARIANT GLY-505.
RX   PubMed=16472269; DOI=10.1111/j.1445-5994.2005.01013.x;
RA   Muessig K., Harzer K., Mayrhofer H., Kraegeloh-Mann I., Haering H.-U.,
RA   Machicao F.;
RT   "Clinical findings in Niemann-Pick disease type B.";
RL   Intern. Med. J. 36:135-136(2006).
RN   [34]
RP   CHARACTERIZATION OF VARIANTS NPDA PRO-302 AND LEU-496,
RP   CHARACTERIZATION OF VARIANTS NPDB TYR-421 AND ARG-608 DEL, FUNCTION,
RP   SUBCELLULAR LOCATION, AND CATALYTIC ACTIVITY.
RX   PubMed=18815062; DOI=10.1016/j.ymgme.2008.08.004;
RA   Jones I., He X., Katouzian F., Darroch P.I., Schuchman E.H.;
RT   "Characterization of common SMPD1 mutations causing types A and B
RT   Niemann-Pick disease and generation of mutation-specific mouse
RT   models.";
RL   Mol. Genet. Metab. 95:152-162(2008).
RN   [35]
RP   VARIANTS NPDB ARG-330 AND ASP-451.
RX   PubMed=19050888; DOI=10.1007/s00277-008-0648-8;
RA   Lan M.Y., Lin S.J., Chen Y.F., Peng C.H., Liu Y.F.;
RT   "A novel missense mutation of the SMPD1 gene in a Taiwanese patient
RT   with type B Niemann-Pick disease.";
RL   Ann. Hematol. 88:695-697(2009).
RN   [36]
RP   VARIANTS NPDA SER-245; CYS-367; PHE-390 DEL; ARG-421; SER-467; GLU-482
RP   AND THR-592 DEL, AND VARIANTS NPDB CYS-228; HIS-376; TRP-474; ALA-486
RP   AND ARG-608 DEL.
RX   PubMed=19405096; DOI=10.1002/humu.21018;
RA   Rodriguez-Pascau L., Gort L., Schuchman E.H., Vilageliu L.,
RA   Grinberg D., Chabas A.;
RT   "Identification and characterization of SMPD1 mutations causing
RT   Niemann-Pick types A and B in Spanish patients.";
RL   Hum. Mutat. 30:1117-1122(2009).
RN   [37]
RP   VARIANTS NPDA ARG-209 AND HIS-251, VARIANTS NPDB MET-312; ARG-425 AND
RP   HIS-523, CHARACTERIZATION OF VARIANTS NPDA ARG-209 AND HIS-251, AND
RP   CHARACTERIZATION OF VARIANTS NPDB MET-312; ARG-425 AND HIS-523.
RX   PubMed=20386867; DOI=10.2119/molmed.2010.00017;
RA   Desnick J.P., Kim J., He X., Wasserstein M.P., Simonaro C.M.,
RA   Schuchman E.H.;
RT   "Identification and characterization of eight novel SMPD1 mutations
RT   causing types A and B Niemann-Pick disease.";
RL   Mol. Med. 16:316-321(2010).
RN   [38]
RP   VARIANT NPDB PRO-161.
RX   PubMed=21621718; DOI=10.1016/S0140-6736(11)60285-7;
RA   Meersseman W., Verschueren P., Tousseyn T., De Vos R., Cassiman D.;
RT   "PAS-positive macrophages--not always infection.";
RL   Lancet 377:1890-1890(2011).
RN   [39]
RP   VARIANT NPDB SER-520.
RX   PubMed=22613662;
RA   Hua R., Wu H., Cui Z., Chen J.X., Wang Z.;
RT   "A novel SMPD1 mutation in two Chinese sibling patients with type B
RT   Niemann-Pick disease.";
RL   Chin. Med. J. 125:1511-1512(2012).
RN   [40]
RP   VARIANTS NPDA ASP-245 AND LEU-570, AND CHARACTERIZATION OF VARIANTS
RP   NPDA ASP-245 AND LEU-570.
RX   PubMed=23430884; DOI=10.1007/8904_2011_80;
RA   Toth B., Erdos M., Szekely A., Ritli L., Bagossi P., Suemegi J.,
RA   Marodi L.;
RT   "Molecular genetic characterization of novel sphingomyelin
RT   phosphodiesterase 1 mutations causing niemann-pick disease.";
RL   JIMD Rep. 3:125-129(2012).
RN   [41]
RP   VARIANTS NPDB HIS-89; PRO-103; PRO-161; CYS-228; SER-371; PRO-549 AND
RP   ARG-608 DEL, AND VARIANTS NPDA ARG-248; SER-463; LEU-475 AND HIS-537.
RX   PubMed=22818240; DOI=10.1016/j.ymgme.2012.06.015;
RA   Hollak C.E., de Sonnaville E.S., Cassiman D., Linthorst G.E.,
RA   Groener J.E., Morava E., Wevers R.A., Mannens M., Aerts J.M.,
RA   Meersseman W., Akkerman E., Niezen-Koning K.E., Mulder M.F.,
RA   Visser G., Wijburg F.A., Lefeber D., Poorthuis B.J.;
RT   "Acid sphingomyelinase (Asm) deficiency patients in The Netherlands
RT   and Belgium: disease spectrum and natural course in attenuated
RT   patients.";
RL   Mol. Genet. Metab. 107:526-533(2012).
RN   [42]
RP   VARIANTS NPDA ARG-226 AND ARG-385, AND VARIANTS NPDB CYS-228; SER-245;
RP   HIS-376; TRP-474; SER-490; PHE-597 AND ARG-608 DEL.
RX   PubMed=23252888; DOI=10.1111/cge.12076;
RA   Irun P., Mallen M., Dominguez C., Rodriguez-Sureda V.,
RA   Alvarez-Sala L.A., Arslan N., Bermejo N., Guerrero C.,
RA   Perez de Soto I., Villalon L., Giraldo P., Pocovi M.;
RT   "Identification of seven novel SMPD1 mutations causing Niemann-Pick
RT   disease types A and B.";
RL   Clin. Genet. 84:356-361(2013).
RN   [43]
RP   CHARACTERIZATION OF VARIANT NPDB ALA-323, AND CHARACTERIZATION OF
RP   VARIANT VAL-485.
RX   PubMed=23430512; DOI=10.1007/8904_2012_147;
RA   Rhein C., Naumann J., Muehle C., Zill P., Adli M., Hegerl U.,
RA   Hiemke C., Mergl R., Moeller H.J., Reichel M., Kornhuber J.;
RT   "The acid sphingomyelinase sequence variant p.A487V is not associated
RT   with decreased levels of enzymatic activity.";
RL   JIMD Rep. 8:1-6(2013).
RN   [44]
RP   VARIANTS ALA-36; PHE-508 AND GLY-603, VARIANTS NPDA ARG-214; CYS-228;
RP   SER-253; ARG-317; PRO-322; ARG-341; ARG-361; HIS-389; ARG-391;
RP   SER-424; ILE-492; HIS-496; ARG-533 AND HIS-600, AND VARIANTS NPDB
RP   PRO-103; PHE-280; ASP-318; CYS-367; SER-463; LEU-518 AND LYS-547.
RX   PubMed=27338287; DOI=10.1002/ajmg.a.37817;
RA   Ranganath P., Matta D., Bhavani G.S., Wangnekar S., Jain J.M.,
RA   Verma I.C., Kabra M., Puri R.D., Danda S., Gupta N., Girisha K.M.,
RA   Sankar V.H., Patil S.J., Ramadevi A.R., Bhat M., Gowrishankar K.,
RA   Mandal K., Aggarwal S., Tamhankar P.M., Tilak P., Phadke S.R.,
RA   Dalal A.;
RT   "Spectrum of SMPD1 mutations in Asian-Indian patients with acid
RT   sphingomyelinase (ASM)-deficient Niemann-Pick disease.";
RL   Am. J. Med. Genet. A 170:2719-2730(2016).
RN   [45]
RP   VARIANTS NPDB ILE-256; GLN-474; ASP-575; ARG-596 AND CYS-608, VARIANT
RP   NPDA PHE-480 DEL, AND REVIEW ON VARIANTS.
RX   PubMed=26499107; DOI=10.1002/humu.22923;
RA   Zampieri S., Filocamo M., Pianta A., Lualdi S., Gort L., Coll M.J.,
RA   Sinnott R., Geberhiwot T., Bembi B., Dardis A.;
RT   "SMPD1 mutation update: database and comprehensive analysis of
RT   published and novel variants.";
RL   Hum. Mutat. 37:139-147(2016).
RN   [46]
RP   CHARACTERIZATION OF VARIANT NPDB ALA-323, CHARACTERIZATION OF VARIANTS
RP   ALA-36; VAL-485 AND ARG-506, AND CATALYTIC ACTIVITY.
RX   PubMed=26084044; DOI=10.3390/ijms160613649;
RA   Rhein C., Muehle C., Kornhuber J., Reichel M.;
RT   "Alleged detrimental mutations in the SMPD1 gene in patients with
RT   Niemann-Pick disease.";
RL   Int. J. Mol. Sci. 16:13649-13652(2015).
CC   -!- FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600,
CC       PubMed:18815062, PubMed:27659707, PubMed:25920558). Also has
CC       phospholipase C activities toward 1,2-diacylglycerolphosphocholine
CC       and 1,2-diacylglycerolphosphoglycerol.
CC       {ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062,
CC       ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,
CC       ECO:0000305}.
CC   -!- FUNCTION: Isoform 2 lacks residues that bind the cofactor Zn(2+)
CC       and has no enzyme activity. {ECO:0000269|PubMed:1840600,
CC       ECO:0000305}.
CC   -!- FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+)
CC       and has no enzyme activity. {ECO:0000269|PubMed:1840600,
CC       ECO:0000305}.
CC   -!- CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +
CC       phosphocholine. {ECO:0000269|PubMed:15877209,
CC       ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:1840600,
CC       ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:26084044,
CC       ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:8702487}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:8702487};
CC       Note=Binds 2 Zn(2+) ions per subunit (PubMed:27349982,
CC       PubMed:27725636). Zn(2+) is particularly important for enzyme
CC       activity at neutral pH (PubMed:8702487).
CC       {ECO:0000269|PubMed:27349982, ECO:0000269|PubMed:27725636,
CC       ECO:0000269|PubMed:8702487};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:27349982}.
CC   -!- INTERACTION:
CC       P55210:CASP7; NbExp=6; IntAct=EBI-7095800, EBI-523958;
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:18815062,
CC       ECO:0000269|PubMed:27659707}. Secreted
CC       {ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707,
CC       ECO:0000269|PubMed:8702487}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=ASM-1;
CC         IsoId=P17405-1; Sequence=Displayed;
CC         Note=Most abundant (90%).;
CC       Name=2; Synonyms=ASM-2;
CC         IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;
CC         Note=Intermediate abundance (10%).;
CC       Name=3; Synonyms=ASM-3;
CC         IsoId=P17405-3; Sequence=VSP_000333;
CC         Note=Low abundance (<1%).;
CC       Name=4;
CC         IsoId=P17405-4; Sequence=VSP_046964;
CC   -!- POLYMORPHISM: A common polymorphism arises from a variable number
CC       of hexanucleotide repeat sequence within the signal peptide
CC       region.
CC   -!- DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-
CC       onset lysosomal storage disorder caused by failure to hydrolyze
CC       sphingomyelin to ceramide. It results in the accumulation of
CC       sphingomyelin and other metabolically related lipids in
CC       reticuloendothelial and other cell types throughout the body,
CC       leading to cell death. Niemann-Pick disease type A is a primarily
CC       neurodegenerative disorder characterized by onset within the first
CC       year of life, mental retardation, digestive disorders, failure to
CC       thrive, major hepatosplenomegaly, and severe neurologic symptoms.
CC       The severe neurological disorders and pulmonary infections lead to
CC       an early death, often around the age of four. Clinical features
CC       are variable. A phenotypic continuum exists between type A (basic
CC       neurovisceral) and type B (purely visceral) forms of Niemann-Pick
CC       disease, and the intermediate types encompass a cluster of
CC       variants combining clinical features of both types A and B.
CC       {ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,
CC       ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,
CC       ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,
CC       ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096,
CC       ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867,
CC       ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888,
CC       ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107,
CC       ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412,
CC       ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onset
CC       lysosomal storage disorder caused by failure to hydrolyze
CC       sphingomyelin to ceramide. It results in the accumulation of
CC       sphingomyelin and other metabolically related lipids in
CC       reticuloendothelial and other cell types throughout the body,
CC       leading to cell death. Clinical signs involve only visceral
CC       organs. The most constant sign is hepatosplenomegaly which can be
CC       associated with pulmonary symptoms. Patients remain free of
CC       neurologic manifestations. However, a phenotypic continuum exists
CC       between type A (basic neurovisceral) and type B (purely visceral)
CC       forms of Niemann-Pick disease, and the intermediate types
CC       encompass a cluster of variants combining clinical features of
CC       both types A and B. In Niemann-Pick disease type B, onset of the
CC       first symptoms occurs in early childhood and patients can survive
CC       into adulthood. {ECO:0000269|PubMed:12369017,
CC       ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,
CC       ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,
CC       ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,
CC       ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770,
CC       ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096,
CC       ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718,
CC       ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240,
CC       ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512,
CC       ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044,
CC       ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287,
CC       ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942,
CC       ECO:0000269|PubMed:8664904}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: There are two types of sphingomyelinases: ASM
CC       (acid), and NSM (neutral).
CC   -!- SIMILARITY: Belongs to the acid sphingomyelinase family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Variants Gln-294 and Val-485 have been originally
CC       reported as disease-causing mutations in NPDA and NPDB
CC       (PubMed:12369017, PubMed:15221801). These variants have been
CC       reclassified as benign polymorphisms (PubMed:23430512).
CC       {ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:15221801,
CC       ECO:0000269|PubMed:23430512}.
CC   -!- WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase
CC       1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database
CC       (LOVD);
CC       URL="http://www.lovd.nl/SMPD1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M59916; AAA58377.1; -; mRNA.
DR   EMBL; M59917; AAA58378.1; -; Genomic_DNA.
DR   EMBL; X63600; CAA45145.1; -; Genomic_DNA.
DR   EMBL; M81780; AAA75008.1; -; Genomic_DNA.
DR   EMBL; M81780; AAA75009.1; -; Genomic_DNA.
DR   EMBL; X59960; CAA42584.1; -; mRNA.
DR   EMBL; AK292388; BAF85077.1; -; mRNA.
DR   EMBL; AC068733; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X52678; CAA36901.1; -; mRNA.
DR   EMBL; X52679; CAA36902.1; -; mRNA.
DR   PIR; S06958; S06958.
DR   PIR; S27009; A39825.
DR   RefSeq; NP_000534.3; NM_000543.4.
DR   RefSeq; NP_001007594.2; NM_001007593.2.
DR   RefSeq; NP_001305016.1; NM_001318087.1.
DR   RefSeq; NP_001305017.1; NM_001318088.1.
DR   UniGene; Hs.498173; -.
DR   PDB; 5I81; X-ray; 2.25 A; A=47-629.
DR   PDB; 5I85; X-ray; 2.50 A; A=47-629.
DR   PDB; 5I8R; X-ray; 3.65 A; A/B/C=47-629.
DR   PDB; 5JG8; X-ray; 2.80 A; A/B=47-629.
DR   PDBsum; 5I81; -.
DR   PDBsum; 5I85; -.
DR   PDBsum; 5I8R; -.
DR   PDBsum; 5JG8; -.
DR   ProteinModelPortal; P17405; -.
DR   SMR; P17405; -.
DR   BioGrid; 112493; 14.
DR   IntAct; P17405; 7.
DR   MINT; MINT-3008689; -.
DR   STRING; 9606.ENSP00000340409; -.
DR   BindingDB; P17405; -.
DR   ChEMBL; CHEMBL2760; -.
DR   DrugBank; DB00381; Amlodipine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01151; Desipramine.
DR   iPTMnet; P17405; -.
DR   PhosphoSitePlus; P17405; -.
DR   BioMuta; SMPD1; -.
DR   DMDM; 224471897; -.
DR   MaxQB; P17405; -.
DR   PaxDb; P17405; -.
DR   PeptideAtlas; P17405; -.
DR   PRIDE; P17405; -.
DR   DNASU; 6609; -.
DR   Ensembl; ENST00000342245; ENSP00000340409; ENSG00000166311.
DR   Ensembl; ENST00000527275; ENSP00000435350; ENSG00000166311.
DR   GeneID; 6609; -.
DR   KEGG; hsa:6609; -.
DR   UCSC; uc001mcw.4; human. [P17405-1]
DR   CTD; 6609; -.
DR   DisGeNET; 6609; -.
DR   GeneCards; SMPD1; -.
DR   GeneReviews; SMPD1; -.
DR   HGNC; HGNC:11120; SMPD1.
DR   MalaCards; SMPD1; -.
DR   MIM; 257200; phenotype.
DR   MIM; 607608; gene.
DR   MIM; 607616; phenotype.
DR   neXtProt; NX_P17405; -.
DR   Orphanet; 77292; Niemann-Pick disease type A.
DR   Orphanet; 77293; Niemann-Pick disease type B.
DR   PharmGKB; PA35969; -.
DR   eggNOG; KOG3770; Eukaryota.
DR   eggNOG; ENOG410YYPB; LUCA.
DR   HOVERGEN; HBG004288; -.
DR   InParanoid; P17405; -.
DR   KO; K12350; -.
DR   OrthoDB; EOG091G03M6; -.
DR   PhylomeDB; P17405; -.
DR   TreeFam; TF313674; -.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   SIGNOR; P17405; -.
DR   ChiTaRS; SMPD1; human.
DR   GeneWiki; Sphingomyelin_phosphodiesterase_1; -.
DR   GenomeRNAi; 6609; -.
DR   PRO; PR:P17405; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000166311; -.
DR   CleanEx; HS_SMPD1; -.
DR   ExpressionAtlas; P17405; baseline and differential.
DR   Genevisible; P17405; HS.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0042599; C:lamellar body; IEA:Ensembl.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0061750; F:acid sphingomyelin phosphodiesterase activity; IDA:UniProtKB.
DR   GO; GO:0016798; F:hydrolase activity, acting on glycosyl bonds; IEA:UniProtKB-KW.
DR   GO; GO:0004767; F:sphingomyelin phosphodiesterase activity; TAS:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0046513; P:ceramide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IMP:BHF-UCL.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006685; P:sphingomyelin catabolic process; IDA:UniProtKB.
DR   GO; GO:0006684; P:sphingomyelin metabolic process; TAS:ProtInc.
DR   GO; GO:0023021; P:termination of signal transduction; IMP:BHF-UCL.
DR   Gene3D; 3.60.21.10; -; 1.
DR   InterPro; IPR004843; Calcineurin-like_PHP_ApaH.
DR   InterPro; IPR029052; Metallo-depent_PP-like.
DR   InterPro; IPR011001; Saposin-like.
DR   InterPro; IPR008139; SaposinB_dom.
DR   InterPro; IPR011160; Sphingomy_PDE.
DR   Pfam; PF00149; Metallophos; 1.
DR   PIRSF; PIRSF000948; Sphingomy_PDE; 1.
DR   SMART; SM00741; SapB; 1.
DR   SUPFAM; SSF47862; SSF47862; 1.
DR   SUPFAM; SSF56300; SSF56300; 1.
DR   PROSITE; PS50015; SAP_B; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Glycosidase; Hydrolase; Lysosome; Metal-binding;
KW   Neurodegeneration; Niemann-Pick disease; Reference proteome; Secreted;
KW   Signal; Zinc.
FT   SIGNAL        1     46
FT   CHAIN        47    629       Sphingomyelin phosphodiesterase.
FT                                /FTId=PRO_0000002323.
FT   DOMAIN       85    169       Saposin B-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00415}.
FT   METAL       206    206       Zinc 1. {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000269|PubMed:27349982}.
FT   METAL       208    208       Zinc 1; via tele nitrogen.
FT                                {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000269|PubMed:27349982}.
FT   METAL       278    278       Zinc 1. {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000269|PubMed:27349982}.
FT   METAL       278    278       Zinc 2. {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000269|PubMed:27349982}.
FT   METAL       318    318       Zinc 2. {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000269|PubMed:27349982}.
FT   METAL       425    425       Zinc 2; via tele nitrogen.
FT                                {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000269|PubMed:27349982}.
FT   METAL       457    457       Zinc 2; via pros nitrogen.
FT                                {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000269|PubMed:27349982}.
FT   METAL       459    459       Zinc 1; via tele nitrogen.
FT                                {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000269|PubMed:27349982}.
FT   CARBOHYD     86     86       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:27349982,
FT                                ECO:0000269|PubMed:9030779}.
FT   CARBOHYD    175    175       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:27349982,
FT                                ECO:0000269|PubMed:9030779}.
FT   CARBOHYD    335    335       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:27349982,
FT                                ECO:0000269|PubMed:9030779}.
FT   CARBOHYD    395    395       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:27349982,
FT                                ECO:0000269|PubMed:9030779}.
FT   CARBOHYD    503    503       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000269|PubMed:27349982}.
FT   CARBOHYD    520    520       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:5I81,
FT                                ECO:0000244|PDB:5I85,
FT                                ECO:0000244|PDB:5I8R,
FT                                ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:27349982,
FT                                ECO:0000269|PubMed:9030779}.
FT   DISULFID     89    165       {ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:27349982}.
FT   DISULFID     92    157       {ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:27349982}.
FT   DISULFID    120    131       {ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268,
FT                                ECO:0000269|PubMed:27349982}.
FT   DISULFID    221    226       {ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268,
FT                                ECO:0000269|PubMed:27349982}.
FT   DISULFID    227    250       {ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268,
FT                                ECO:0000269|PubMed:27349982}.
FT   DISULFID    385    431       {ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268,
FT                                ECO:0000269|PubMed:27349982}.
FT   DISULFID    584    588       {ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268,
FT                                ECO:0000269|PubMed:27349982}.
FT   DISULFID    594    607       {ECO:0000244|PDB:5JG8,
FT                                ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268,
FT                                ECO:0000269|PubMed:27349982}.
FT   VAR_SEQ     104    104       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046964.
FT   VAR_SEQ     363    418       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_000333.
FT   VAR_SEQ     363    374       IGGFYALSPYPG -> YLSSVETQEGKR (in isoform
FT                                2). {ECO:0000305}.
FT                                /FTId=VSP_000331.
FT   VAR_SEQ     375    418       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_000332.
FT   VARIANT      36     36       V -> A (polymorphism; does not affect
FT                                enzymatic activity; dbSNP:rs1050228).
FT                                {ECO:0000269|PubMed:1740330,
FT                                ECO:0000269|PubMed:26084044,
FT                                ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_038191.
FT   VARIANT      49     49       D -> V (in NPDB; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060870.
FT   VARIANT      89     89       C -> H (in NPDB; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:22818240}.
FT                                /FTId=VAR_075322.
FT   VARIANT      92     92       C -> W (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060871.
FT   VARIANT     103    103       L -> P (in NPDA and NPDB; expresses
FT                                protein level comparable to wild-type
FT                                SMPD1 expressing cells; retains very low
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:15221801,
FT                                ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:16010684,
FT                                ECO:0000269|PubMed:22818240,
FT                                ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_060872.
FT   VARIANT     130    130       V -> A (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains 13% residual enzyme
FT                                activity). {ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060873.
FT   VARIANT     137    137       L -> P (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060874.
FT   VARIANT     157    157       C -> R (in NPDB).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:8407868}.
FT                                /FTId=VAR_011387.
FT   VARIANT     161    161       L -> P (in NPDB).
FT                                {ECO:0000269|PubMed:22818240}.
FT                                /FTId=VAR_075323.
FT   VARIANT     166    166       G -> R (in NPDB; also in patients with an
FT                                intermediate form).
FT                                {ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:16472269}.
FT                                /FTId=VAR_060875.
FT   VARIANT     176    176       I -> N (in NPDB).
FT                                {ECO:0000269|PubMed:16472269}.
FT                                /FTId=VAR_060876.
FT   VARIANT     184    184       P -> L (in NPDA; reduces enzyme activity;
FT                                intermediate form with clinical features
FT                                of both Niemann-Pick disease types A and
FT                                B). {ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060877.
FT   VARIANT     196    196       A -> P (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060878.
FT   VARIANT     200    200       R -> C (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060879.
FT   VARIANT     209    209       W -> R (in NPDA; results in less than
FT                                0.5% of wild-type activity).
FT                                {ECO:0000269|PubMed:20386867}.
FT                                /FTId=VAR_068435.
FT   VARIANT     214    214       L -> R (in NPDA).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077311.
FT   VARIANT     225    225       L -> M (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060880.
FT   VARIANT     225    225       L -> P (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains no enzyme activity).
FT                                {ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060881.
FT   VARIANT     226    226       C -> R (in NPDA).
FT                                {ECO:0000269|PubMed:23252888}.
FT                                /FTId=VAR_075324.
FT   VARIANT     228    228       R -> C (in NPDB and NPDA; some patients
FT                                have a NPDA/NPDB intermediate phenotype).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:19405096,
FT                                ECO:0000269|PubMed:22818240,
FT                                ECO:0000269|PubMed:23252888,
FT                                ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_060882.
FT   VARIANT     228    228       R -> H (in NPDA; intermediate form with
FT                                clinical features of both Niemann-Pick
FT                                disease types A and B).
FT                                {ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060883.
FT   VARIANT     232    232       G -> D (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060884.
FT   VARIANT     241    241       A -> V (in NPDA; intermediate form with
FT                                clinical features of both Niemann-Pick
FT                                disease types A and B).
FT                                {ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060885.
FT   VARIANT     242    242       G -> R (in NPDB).
FT                                {ECO:0000269|PubMed:1618760}.
FT                                /FTId=VAR_005058.
FT   VARIANT     244    244       W -> C (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains no enzyme activity).
FT                                {ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060886.
FT   VARIANT     245    245       G -> D (in NPDA; severe decrease in
FT                                activity; the mutant is highly unstable).
FT                                {ECO:0000269|PubMed:23430884}.
FT                                /FTId=VAR_075325.
FT   VARIANT     245    245       G -> S (in NPDA and NPDB).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:15221801,
FT                                ECO:0000269|PubMed:19405096,
FT                                ECO:0000269|PubMed:23252888}.
FT                                /FTId=VAR_060887.
FT   VARIANT     246    246       E -> K (in NPDA).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060888.
FT   VARIANT     246    246       E -> Q (in NPDB; 30% residual activity).
FT                                {ECO:0000269|PubMed:8664904}.
FT                                /FTId=VAR_005059.
FT   VARIANT     248    248       S -> R (in NPDA and NPDB; also found in
FT                                patients with an intermediate form).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:12556236,
FT                                ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:22818240}.
FT                                /FTId=VAR_015287.
FT   VARIANT     251    251       D -> E (in NPDA; strongly reduces enzyme
FT                                activity; intermediate form with clinical
FT                                features of both Niemann-Pick disease
FT                                types A and B).
FT                                {ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060889.
FT   VARIANT     251    251       D -> H (in NPDA; results in loss of
FT                                activity). {ECO:0000269|PubMed:20386867}.
FT                                /FTId=VAR_068436.
FT   VARIANT     253    253       P -> S (in NPDA).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077312.
FT   VARIANT     256    256       T -> I (in NPDB).
FT                                {ECO:0000269|PubMed:26499107}.
FT                                /FTId=VAR_075326.
FT   VARIANT     278    278       D -> A (in NPDA; strongly reduces enzyme
FT                                activity; intermediate form with clinical
FT                                features of both Niemann-Pick disease
FT                                types A and B).
FT                                {ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060890.
FT   VARIANT     280    280       P -> F (in NPDB; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077313.
FT   VARIANT     281    281       A -> T (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains no enzyme activity).
FT                                {ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060891.
FT   VARIANT     289    289       R -> H (in NPDB; also in patients with an
FT                                intermediate form; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060892.
FT   VARIANT     292    292       Q -> K (in NPDA; strongly reduces enzyme
FT                                activity; intermediate form with clinical
FT                                features of both Niemann-Pick disease
FT                                types A and B).
FT                                {ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:9266408}.
FT                                /FTId=VAR_060893.
FT   VARIANT     294    294       R -> Q (in dbSNP:rs35824453).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060894.
FT   VARIANT     302    302       L -> P (in NPDA; in 23% of NPDA Ashkenazi
FT                                Jewish patients; abolishes enzyme
FT                                activity). {ECO:0000269|PubMed:1391960,
FT                                ECO:0000269|PubMed:18815062}.
FT                                /FTId=VAR_005060.
FT   VARIANT     312    312       V -> M (in NPDB; results in 20% of wild-
FT                                type activity).
FT                                {ECO:0000269|PubMed:20386867}.
FT                                /FTId=VAR_068437.
FT   VARIANT     313    313       Y -> H (in NPDA).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060895.
FT   VARIANT     316    316       V -> E (in dbSNP:rs12575136).
FT                                /FTId=VAR_054642.
FT   VARIANT     317    317       G -> R (in NPDA).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077314.
FT   VARIANT     318    318       N -> D (in NPDB; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077315.
FT   VARIANT     319    319       H -> Y (in NPDA).
FT                                {ECO:0000269|PubMed:12556236,
FT                                ECO:0000269|PubMed:22818240}.
FT                                /FTId=VAR_015288.
FT   VARIANT     322    322       T -> I (in dbSNP:rs1050233).
FT                                {ECO:0000269|PubMed:1840600,
FT                                ECO:0000269|PubMed:2555181,
FT                                ECO:0000269|PubMed:26084044}.
FT                                /FTId=VAR_054643.
FT   VARIANT     322    322       T -> P (in NPDA; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077316.
FT   VARIANT     323    323       P -> A (in NPDB; results in 1-4% of wild
FT                                type activity).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:23430512,
FT                                ECO:0000269|PubMed:26084044}.
FT                                /FTId=VAR_060896.
FT   VARIANT     330    330       P -> R (in NPDB).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:19050888}.
FT                                /FTId=VAR_060897.
FT   VARIANT     341    341       L -> P (in NPDA; strongly reduces enzyme
FT                                activity; intermediate form with clinical
FT                                features of both Niemann-Pick disease
FT                                types A and B).
FT                                {ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:9266408}.
FT                                /FTId=VAR_060898.
FT   VARIANT     341    341       L -> R (in NPDA).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077317.
FT   VARIANT     357    357       A -> D (in NPDB; sphingomyelinase
FT                                activity is decreased to 4% of wild-type
FT                                activity; no effect on protein abundance;
FT                                no effect on protein localization to
FT                                lysosome; no effect on protein
FT                                localization to extracellular space).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:25920558,
FT                                ECO:0000269|PubMed:27659707}.
FT                                /FTId=VAR_060899.
FT   VARIANT     361    361       L -> R (in NPDA; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077318.
FT   VARIANT     367    367       Y -> C (in NPDA).
FT                                {ECO:0000269|PubMed:19405096,
FT                                ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_060900.
FT   VARIANT     371    371       P -> S (in NPDB).
FT                                {ECO:0000269|PubMed:12556236,
FT                                ECO:0000269|PubMed:22818240}.
FT                                /FTId=VAR_015289.
FT   VARIANT     376    376       R -> H (in NPDB; reduces enzyme activity;
FT                                some patients have a NPDA/NPDB
FT                                intermediate phenotype).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:19405096,
FT                                ECO:0000269|PubMed:23252888}.
FT                                /FTId=VAR_060901.
FT   VARIANT     376    376       R -> L (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060902.
FT   VARIANT     379    379       S -> P (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060903.
FT   VARIANT     382    382       M -> I (in NPDA and NPDB).
FT                                {ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:1618760}.
FT                                /FTId=VAR_005061.
FT   VARIANT     383    383       N -> S (in NPDB).
FT                                {ECO:0000269|PubMed:1618760}.
FT                                /FTId=VAR_005062.
FT   VARIANT     385    385       C -> R (in NPDA).
FT                                {ECO:0000269|PubMed:23252888}.
FT                                /FTId=VAR_075327.
FT   VARIANT     389    389       N -> H (in NPDA).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077319.
FT   VARIANT     389    389       N -> T (in NPDA).
FT                                {ECO:0000269|PubMed:8680412}.
FT                                /FTId=VAR_005063.
FT   VARIANT     390    390       Missing (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060904.
FT   VARIANT     391    391       W -> G (in NPDB; low sphingomyelin
FT                                degradation rates).
FT                                {ECO:0000269|PubMed:8051942}.
FT                                /FTId=VAR_005064.
FT   VARIANT     391    391       W -> R (in NPDA; intermediate form).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077320.
FT   VARIANT     413    413       A -> V (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060905.
FT   VARIANT     421    421       H -> R (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060906.
FT   VARIANT     421    421       H -> Y (in NPDB; abolishes enzyme
FT                                activity). {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:18815062}.
FT                                /FTId=VAR_015290.
FT   VARIANT     424    424       G -> S (in NPDA).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077321.
FT   VARIANT     425    425       H -> R (in NPDB; results in loss of
FT                                activity; the patient also carries
FT                                mutation H-228 that has sufficient
FT                                activity to account for the Niemann-Pick
FT                                disease type B phenotype).
FT                                {ECO:0000269|PubMed:20386867}.
FT                                /FTId=VAR_068438.
FT   VARIANT     431    431       C -> R (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060907.
FT   VARIANT     432    432       L -> P (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060908.
FT   VARIANT     435    435       W -> C (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060909.
FT   VARIANT     436    436       S -> R (in NPDB).
FT                                {ECO:0000269|PubMed:1301192}.
FT                                /FTId=VAR_005065.
FT   VARIANT     446    446       Y -> C (in NPDA).
FT                                {ECO:0000269|PubMed:8693491}.
FT                                /FTId=VAR_011388.
FT   VARIANT     450    450       L -> P (in NPDA).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060910.
FT   VARIANT     451    451       A -> D (in NPDB).
FT                                {ECO:0000269|PubMed:19050888}.
FT                                /FTId=VAR_068439.
FT   VARIANT     452    452       A -> V (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060911.
FT   VARIANT     456    456       G -> D (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060912.
FT   VARIANT     463    463       F -> S (in NPDA).
FT                                {ECO:0000269|PubMed:12556236,
FT                                ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_015291.
FT   VARIANT     467    467       Y -> S (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060913.
FT   VARIANT     474    474       R -> Q (in NPDB; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26499107}.
FT                                /FTId=VAR_075328.
FT   VARIANT     474    474       R -> W (in NPDB; some patients have a
FT                                NPDA/NPDB intermediate phenotype).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:19405096,
FT                                ECO:0000269|PubMed:23252888}.
FT                                /FTId=VAR_060914.
FT   VARIANT     475    475       P -> L (in NPDA and NPDB).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:12556236,
FT                                ECO:0000269|PubMed:15221801,
FT                                ECO:0000269|PubMed:22818240}.
FT                                /FTId=VAR_015292.
FT   VARIANT     480    480       F -> L (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060915.
FT   VARIANT     480    480       Missing (in NPDA; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26499107}.
FT                                /FTId=VAR_075329.
FT   VARIANT     482    482       A -> E (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060916.
FT   VARIANT     485    485       A -> V (polymorphism; does not affect
FT                                enzymatic activity; dbSNP:rs141641266).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:23430512,
FT                                ECO:0000269|PubMed:26084044}.
FT                                /FTId=VAR_060917.
FT   VARIANT     486    486       T -> A (in NPDB).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060918.
FT   VARIANT     488    488       Y -> N (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060919.
FT   VARIANT     490    490       G -> S (in NPDB).
FT                                {ECO:0000269|PubMed:23252888}.
FT                                /FTId=VAR_075330.
FT   VARIANT     492    492       N -> I (in NPDA; intermediate form).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077322.
FT   VARIANT     494    494       G -> S (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060920.
FT   VARIANT     496    496       R -> C (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060921.
FT   VARIANT     496    496       R -> H (in NPDA).
FT                                {ECO:0000269|PubMed:15221801,
FT                                ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_060922.
FT   VARIANT     496    496       R -> L (in NPDA; in 32% of NPDA Ashkenazi
FT                                Jewish patients; nearly abolishes enzyme
FT                                activity). {ECO:0000269|PubMed:15221801,
FT                                ECO:0000269|PubMed:18815062,
FT                                ECO:0000269|PubMed:2023926}.
FT                                /FTId=VAR_005066.
FT   VARIANT     505    505       S -> G. {ECO:0000269|PubMed:16472269}.
FT                                /FTId=VAR_060923.
FT   VARIANT     506    506       G -> R (polymorphism; does not affect
FT                                enzymatic activity; dbSNP:rs1050239).
FT                                {ECO:0000269|PubMed:1292508,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:1840600,
FT                                ECO:0000269|PubMed:2555181}.
FT                                /FTId=VAR_054644.
FT   VARIANT     508    508       S -> F. {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077323.
FT   VARIANT     514    514       H -> Q (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060924.
FT   VARIANT     515    515       E -> V (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060925.
FT   VARIANT     517    517       Y -> C (in NPDA).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060926.
FT   VARIANT     518    518       I -> L (in NPDB).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077324.
FT   VARIANT     520    520       N -> S (in NPDB).
FT                                {ECO:0000269|PubMed:22613662}.
FT                                /FTId=VAR_068440.
FT   VARIANT     523    523       Q -> H (in NPDB; results in 64% of wild-
FT                                type activity).
FT                                {ECO:0000269|PubMed:20386867}.
FT                                /FTId=VAR_068441.
FT   VARIANT     533    533       W -> R (in NPDB and NPDA; also in
FT                                patients with an intermediate form).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_060927.
FT   VARIANT     537    537       Y -> H (in NPDA).
FT                                {ECO:0000269|PubMed:12556236,
FT                                ECO:0000269|PubMed:22818240}.
FT                                /FTId=VAR_015293.
FT   VARIANT     547    547       N -> K (in NPDB).
FT                                {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077325.
FT   VARIANT     549    549       L -> P (in NPDB).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:22818240}.
FT                                /FTId=VAR_060928.
FT   VARIANT     563    563       D -> Y (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains 6.8% residual enzyme
FT                                activity). {ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060929.
FT   VARIANT     570    570       F -> L (in NPDA; results in decreased
FT                                activity; decreased stability).
FT                                {ECO:0000269|PubMed:23430884}.
FT                                /FTId=VAR_075331.
FT   VARIANT     575    575       H -> D (in NPDB; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26499107}.
FT                                /FTId=VAR_075332.
FT   VARIANT     576    576       K -> N (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060930.
FT   VARIANT     577    577       G -> S (in NPDA; impairs enzyme activity;
FT                                also in patients with an intermediate
FT                                form). {ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:1718266}.
FT                                /FTId=VAR_005067.
FT   VARIANT     592    592       Missing (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060931.
FT   VARIANT     596    596       Q -> R (in NPDB).
FT                                {ECO:0000269|PubMed:26499107}.
FT                                /FTId=VAR_075333.
FT   VARIANT     597    597       L -> F (in NPDB; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23252888}.
FT                                /FTId=VAR_075334.
FT   VARIANT     600    600       R -> H (in NPDB and NPDA; expresses
FT                                protein level comparable to wild-type
FT                                SMPD1 expressing cells; retains about 10%
FT                                residual enzyme activity).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:16010684,
FT                                ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_060932.
FT   VARIANT     600    600       R -> P (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains very low enzyme activity).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060933.
FT   VARIANT     603    603       S -> G. {ECO:0000269|PubMed:27338287}.
FT                                /FTId=VAR_077326.
FT   VARIANT     608    608       R -> C (in NPDB; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26499107}.
FT                                /FTId=VAR_075335.
FT   VARIANT     608    608       Missing (in NPDB; nearly abolishes enzyme
FT                                activity; some patients have a NPDA/NPDB
FT                                intermediate phenotype).
FT                                {ECO:0000269|PubMed:12556236,
FT                                ECO:0000269|PubMed:18815062,
FT                                ECO:0000269|PubMed:1885770,
FT                                ECO:0000269|PubMed:19405096,
FT                                ECO:0000269|PubMed:22818240,
FT                                ECO:0000269|PubMed:23252888}.
FT                                /FTId=VAR_005068.
FT   CONFLICT     35     36       Missing (in Ref. 4; CAA42584).
FT                                {ECO:0000305}.
FT   CONFLICT    268    268       G -> D (in Ref. 5; BAF85077).
FT                                {ECO:0000305}.
FT   HELIX        85     87       {ECO:0000244|PDB:5I81}.
FT   HELIX        88    103       {ECO:0000244|PDB:5I81}.
FT   HELIX       106    122       {ECO:0000244|PDB:5I81}.
FT   HELIX       128    148       {ECO:0000244|PDB:5I81}.
FT   TURN        149    151       {ECO:0000244|PDB:5I81}.
FT   HELIX       153    161       {ECO:0000244|PDB:5I81}.
FT   TURN        163    165       {ECO:0000244|PDB:5I81}.
FT   STRAND      198    204       {ECO:0000244|PDB:5I81}.
FT   STRAND      222    225       {ECO:0000244|PDB:5I81}.
FT   STRAND      247    249       {ECO:0000244|PDB:5I81}.
FT   HELIX       254    262       {ECO:0000244|PDB:5I81}.
FT   HELIX       265    267       {ECO:0000244|PDB:5I81}.
FT   STRAND      271    275       {ECO:0000244|PDB:5I81}.
FT   HELIX       289    307       {ECO:0000244|PDB:5I81}.
FT   STRAND      312    314       {ECO:0000244|PDB:5I81}.
FT   STRAND      320    323       {ECO:0000244|PDB:5I81}.
FT   STRAND      334    338       {ECO:0000244|PDB:5JG8}.
FT   HELIX       339    348       {ECO:0000244|PDB:5I81}.
FT   TURN        350    352       {ECO:0000244|PDB:5I81}.
FT   HELIX       355    364       {ECO:0000244|PDB:5I81}.
FT   STRAND      367    372       {ECO:0000244|PDB:5I81}.
FT   STRAND      375    379       {ECO:0000244|PDB:5I81}.
FT   HELIX       382    385       {ECO:0000244|PDB:5I81}.
FT   HELIX       390    393       {ECO:0000244|PDB:5I81}.
FT   HELIX       399    401       {ECO:0000244|PDB:5I81}.
FT   HELIX       402    416       {ECO:0000244|PDB:5I81}.
FT   STRAND      419    423       {ECO:0000244|PDB:5I81}.
FT   HELIX       428    430       {ECO:0000244|PDB:5I81}.
FT   HELIX       433    445       {ECO:0000244|PDB:5I81}.
FT   TURN        446    449       {ECO:0000244|PDB:5I81}.
FT   STRAND      450    455       {ECO:0000244|PDB:5I81}.
FT   STRAND      462    467       {ECO:0000244|PDB:5I81}.
FT   TURN        469    471       {ECO:0000244|PDB:5I81}.
FT   STRAND      474    481       {ECO:0000244|PDB:5I81}.
FT   TURN        488    490       {ECO:0000244|PDB:5I81}.
FT   STRAND      494    501       {ECO:0000244|PDB:5I81}.
FT   STRAND      511    518       {ECO:0000244|PDB:5I81}.
FT   HELIX       521    524       {ECO:0000244|PDB:5I81}.
FT   STRAND      534    538       {ECO:0000244|PDB:5I81}.
FT   HELIX       539    543       {ECO:0000244|PDB:5I81}.
FT   HELIX       550    561       {ECO:0000244|PDB:5I81}.
FT   HELIX       564    574       {ECO:0000244|PDB:5I81}.
FT   TURN        575    577       {ECO:0000244|PDB:5I81}.
FT   HELIX       586    597       {ECO:0000244|PDB:5I81}.
FT   STRAND      600    602       {ECO:0000244|PDB:5JG8}.
FT   HELIX       604    607       {ECO:0000244|PDB:5I81}.
FT   TURN        608    610       {ECO:0000244|PDB:5I81}.
SQ   SEQUENCE   629 AA;  69752 MW;  C9888CB8359C42AC CRC64;
     MPRYGASLRQ SCPRSGREQG QDGTAGAPGL LWMGLVLALA LALALALSDS RVLWAPAEAH
     PLSPQGHPAR LHRIVPRLRD VFGWGNLTCP ICKGLFTAIN LGLKKEPNVA RVGSVAIKLC
     NLLKIAPPAV CQSIVHLFED DMVEVWRRSV LSPSEACGLL LGSTCGHWDI FSSWNISLPT
     VPKPPPKPPS PPAPGAPVSR ILFLTDLHWD HDYLEGTDPD CADPLCCRRG SGLPPASRPG
     AGYWGEYSKC DLPLRTLESL LSGLGPAGPF DMVYWTGDIP AHDVWHQTRQ DQLRALTTVT
     ALVRKFLGPV PVYPAVGNHE STPVNSFPPP FIEGNHSSRW LYEAMAKAWE PWLPAEALRT
     LRIGGFYALS PYPGLRLISL NMNFCSRENF WLLINSTDPA GQLQWLVGEL QAAEDRGDKV
     HIIGHIPPGH CLKSWSWNYY RIVARYENTL AAQFFGHTHV DEFEVFYDEE TLSRPLAVAF
     LAPSATTYIG LNPGYRVYQI DGNYSGSSHV VLDHETYILN LTQANIPGAI PHWQLLYRAR
     ETYGLPNTLP TAWHNLVYRM RGDMQLFQTF WFLYHKGHPP SEPCGTPCRL ATLCAQLSAR
     ADSPALCRHL MPDGSLPEAQ SLWPRPLFC
//
